| How big is the aurora kinase b market today, and what are its future growth expectations?
The aurora kinase b market size has grown rapidly in recent years. It will grow from $1.14 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing demand for targeted cancer therapies, a rise in the prevalence of cancer globally, increasing investments in precision medicine, growth in the number of clinical trials, and growth in government funding for cancer research. The aurora kinase b market size is expected to see rapid growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to rising investments in innovative cancer treatment, rising incidence of drug-resistant cancers, growing research and development, rising demand for combination therapies, and rising prevalence of solid tumors. Major trends in the forecast period include technological advancements, precision medicine, novel therapies, data analytics, and novel therapies. Get Your Free Sample of The Global Aurora Kinase B Market Report: The rising incidence of cancer is expected to propel the growth of the aurora kinase B market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade surrounding tissues and metastasize to other parts of the body. Cancer cases are rising due to factors such as an aging population, lifestyle changes, environmental exposures, and improved detection and diagnosis. Aurora kinase B plays a critical role in mitosis, and its overexpression is linked to chromosomal instability and cancer progression. It is often targeted in cancer therapies due to its involvement in tumor cell division. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 20 million new cancer cases were reported in 2022, along with 9.7 million deaths. By 2050, new cancer cases are expected to exceed 35 million, representing a 77% increase from 2022. Therefore, the rising incidence of cancer is driving the growth of the aurora kinase B market. What are the key segments within the aurora kinase b market? 1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types Subsegments: Order your report now for swift delivery Major companies operating in the aurora kinase B market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc How will emerging trends drive the aurora kinase b market throughout the forecast period? Major companies operating in the aurora kinase B market are developing innovative products, such as aurora kinase inhibitors, to specifically target and disrupt crucial processes in cell division. Aurora kinase inhibitors are drugs designed to block the activity of Aurora kinases, which are critical for cell division, thereby disrupting the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for its EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is being developed as a treatment for acute myeloid leukemia (AML) and acts as an inhibitor targeting both FLT3 and Aurora kinase. This approach is specifically designed for AML patients who have developed resistance to FLT3 inhibitors. Research has demonstrated that dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition both in vitro and in vivo. How do regional factors impact the aurora kinase b market, and which region is the largest contributor? North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. What Does The Aurora Kinase B Market Report 2025 Offer? The aurora kinase b market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities. Aurora kinase B is a protein enzyme that plays a critical role in cell division, particularly during mitosis. It is involved in regulating chromosome alignment, segregation, and the proper distribution of genetic material to daughter cells. Aurora kinase B is essential for maintaining genomic stability, and its dysregulation is often associated with various cancers. Purchase the exclusive report now to unlock valuable market insights: Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making. Contact Us: Follow Us On: |
Future of the Global Aurora Kinase B Market: Growth Projections and Key Trends (2025-2034)
